The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma
Open accessThe DOI matches its Crossref record; 91 of the 93 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor mainly associated with asbestos exposure and is characterized by a very difficult pharmacological approach. One of the molecular mechanisms associated with cancer onset and invasiveness is the epithelial-to-mesenchymal transition (EMT), an event induced by different types of inducers, such as transforming growth factor β (TGFβ), the main inducer of EMT, and oxidative stress. MPM development and metastasis have been correlated to EMT; On one hand, EMT mediates the effects exerted by asbestos fibers in the mesothelium, particularly via increased oxidative stress and TGFβ levels evoked by asbestos exposure, thus promoting a malignant phenotype, and on the other hand, MPM acquires invasiveness via the EMT event, as shown by an upregulation of mesenchymal markers or, although indirectly, some miRNAs or non-coding RNAs, all demonstrated to be involved in cancer onset and metastasis. This review aims to better describe how EMT is involved in driving the development and invasiveness of MPM, in an attempt to open new scenarios that are useful in the identification of predictive markers and to improve the pharmacological approach against this aggressive cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ROS can sustain EMT via TGF-β1 [89].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [89]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Adhikary, G., Grun, D., Alexander, H. R., Friedberg, J. S., Xu, W., Keillor, J. W., Kandasamy, S., & Eckert, R. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26130 · Cited by 40
RetractedNew insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · cited 1×
“In a non-SMAD-dependent way, TGFβ-induced EMT involves some signaling pathways, such as mitogen-activated protein kinase (MAPK), PI3K, NF-κB and small GTPases of the Rho family [4,48,49]; among these non-SMAD signaling pathways, PI3K actives Akt, which inhibits GSK-3β in turn, a regulator of SNAI1, SNAI2, Twist and ZE…”
BackgroundGuidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO reports · doi:10.1038/embor.2008.74 · Cited by 1,722
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · cited 2×
“Currently, a combination of immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), anti-programmed cell death 1 (PD-1), nivolumab and anti-CTL antigen 4 (CTLA-4) ipilimumab [10] was approved by the Food and Drug Administration (FDA) for first-line treatment of unresectable MPM based on CheckMate 743, which…”
BackgroundMethodTGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Malignant cells facilitate lung metastasis by bringing their own soil
Duda, D. G., Duyverman, A. M. M. J., Kohno, M., Snuderl, M., Steller, E. J. A., Fukumura, D., & Jain, R. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016234107 · Cited by 594
Cited by
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
“The exact cause of EMT in mesothelioma remains unclear, but it likely involves the acquisition of genomic abnormalities, positive selection of tumour cells and the tumour microenvironment (TME), which includes stimulation by TGFβ 66 .”
InfluentialFakhri, S., Moradi, S. Z., Faraji, F., Kooshki, L., Webber, K. J., & Bishayee, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10136-9 · Cited by 34
TGF-β as Predictive Marker and Pharmacological Target in Lung Cancer Approach
Ramundo, V., Palazzo, M. L., & Aldieri, E. (2023) · Cancers · doi:10.3390/cancers15082295 · Cited by 35
“In particular, this cytokine is the major driver of the epithelial to mesenchymal transition (EMT), a reversible physiological process involved in tumor onset, progression, and metastasis [8].”
BackgroundSelf-citationAbd‐Elmawla, M. A., Mageed, S. S. A., AL‐Noshokaty, T. M., Elballal, M. S., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Midan, H. M., Rizk, N. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154817 · Cited by 26
Metadata
- Authors
- Ramundo, V., Zanirato, G., & Aldieri, E.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Aldieri, Elisabetta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-11
- Volume
- 22
- Issue
- 22
- Pages
- 12216
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8621591
- OpenAlex
- W3214151214
- Cited by
- 46
- References
- 93
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 14 · 2022: 10
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- epithelial-mesenchymal transition, malignant pleural mesothelioma, asbestos exposure, TGF-beta, oxidative stress, tumor invasion, metastasis, mesenchymal markers, microRNA, non-coding RNA, predictive biomarkers, mesothelium
- MeSH terms
- Mesothelioma, Malignant, Humans, Neoplasm Metastasis, Neoplasm Proteins, Pleural Neoplasms, RNA, Neoplasm, Biomarkers, Tumor, Transforming Growth Factor beta, MicroRNAs, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. https://app.cochat.ai/papers/10.3390/ijms222212216
- The paper
- Ramundo, V., Zanirato, G., & Aldieri, E. (2021). The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222212216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.